659. Can Marty Makary Fix the F.D.A.?

Episode Summary

Executive Summary: The interview presents FDA Commissioner Marty Makary’s agenda to speed drug approvals, use AI and real-world data, cut regulatory delays, and reshape food and health policy under the Trump administration. He defends controversial moves on autism, Tylenol, vaccines, and direct-to-consumer drug ads as science-driven, while arguing the FDA must be more proactive, less bureaucratic, and more willing to challenge medical dogma.

Main Topics: FDA modernization and faster approvals (Priority: 5/5): Makary says the FDA should shift from passive review to proactively finding promising treatments, shortening review timelines from years to weeks, and using market incentives to encourage innovation and lower prices. Food policy and nutrition reform (Priority: 5/5): He argues the FDA is correcting decades of mistaken guidance on saturated fat, ultra-processed foods, sugar, dyes, and school nutrition, including rewriting the food pyramid and SNAP-related policy. AI, data, and regulatory reform (Priority: 4/5): Makary describes agency-wide AI adoption through ELSA, more use of computational modeling and post-market data, and eventual replacement of some animal testing with organ-on-chip methods. Autism, Tylenol, and leovorin controversy (Priority: 5/5): He defends the FDA’s move to update levofloxacin? No—leucovorin labeling for autism and the administration’s warning about acetaminophen in pregnancy, saying both were based on available evidence even if incomplete. Political polarization and 'Trump derangement syndrome' (Priority: 4/5): Makary claims criticism of Trump-era health actions is often reflexively partisan and that media coverage strips away nuance, especially on scientific and medical issues. Health system incentives and drug pricing (Priority: 4/5): He links FDA policy to broader efforts to reduce drug prices, reward domestic manufacturing, and accelerate approvals for companies that match prices in other wealthy countries. Safety, independence, and controversial governance (Priority: 4/5): Makary insists the FDA remains scientifically independent even as it coordinates closely with HHS, NIH, CMS, White House officials, and the administration’s political goals.

Key Arguments: The FDA has become too slow and bureaucratic; review processes should be redesigned so meaningful therapies can be evaluated faster without reducing scientific rigor. The agency should be proactive rather than merely reactive: it should identify promising treatments early and help shepherd them through review. Many long-standing medical and nutritional beliefs were wrong, including early peanut avoidance, low-fat dietary dogma, and excessive reliance on animal testing. AI can improve internal review efficiency, application organization, and scientific analysis, and regulators must adapt quickly or fall behind the technology. Leucovorin for autism is justified by mixed but sufficiently promising clinical and observational evidence, especially given its safety profile and low cost. Claims that the administration is cutting health funding are, in his view, misleading; he says budgets are increasing but being reallocated away from waste and toward research. Direct-to-consumer drug advertising often distorts information by emphasizing benefits while minimizing risks, and the FDA should police deceptive claims more aggressively. The FDA can influence prices and innovation through priority review vouchers and other incentives, especially if companies offer best-in-class pricing or domestic manufacturing. Controversial issues like vaccines, acetaminophen, abortion drugs, and autism should be approached through scientific dialogue rather than taboo or censorship.

Data Points: FDA share of U.S. economy: 20% - McCary says the FDA regulates about 20% of the U.S. economy. Drug approval timeline: 10 to 12 years - He says this is the traditional time it can take for a new drug to come to market. Priority review voucher value: $500 million - He says a priority review voucher has a street value of roughly $500 million. Autism prevalence in California boys: 1 in 12 - He cites this figure to argue autism rates are rising. Veteran suicides per year: 8,000 - He uses this figure when arguing for faster PTSD treatment decisions. Animal testing failure rate after successful animal trials: 90% - He says 90% of drugs that pass animal testing fail human safety/efficacy testing. Monoclonal antibody chimpanzee use: 144 chimpanzees - He claims the average monoclonal antibody uses 144 chimpanzees in testing. AI rollout date target: June 30 - He says ELSA was made available agency-wide ahead of schedule by June 30. Leucovorin safety history: Nearly a century - He describes leucovorin as having been around nearly a century with an impeccable safety profile. Scientific reviewers and inspectors hiring: Nearly 1,000 - He says the FDA is hiring nearly a thousand scientific reviewers and inspectors. Peanut allergy guidance age: Age 3 versus 6–7 months - He contrasts prior advice to avoid peanuts until age three with newer advice to expose infants around six or seven months. NIH budget change claim: Higher next year than this year - He says NIH funding is increasing, not being cut. Medicaid budget claim: +$200 million - He claims Medicaid’s budget has increased by $200 million.

Pivotal Quotes: "The FDA today is not going to be an FDA in a receive-only mode. We're not going to be stingy librarians." — Marty McCary: Describing his vision of a proactive, innovation-seeking FDA. "We want to be an advocate for the American people." — Marty McCary: Explaining why the FDA should prioritize domestic manufacturing, lower prices, and faster access to therapies. "If literally we had discovered and announced the cure for cancer, you would have some people say, well, the Trump administration interfered, they did this too quick, they did it too slow." — Marty McCary: Responding to criticism of Trump-administration health actions and accusing critics of reflexive opposition.

Implications: If Makary’s approach holds, the FDA may become faster, more data-driven, and more politically combative, with major implications for drug development, nutrition policy, AI regulation, and public trust in medical guidance.